Department of Microbiology, Icahn School of Medicine at Mt. Sinai, New York, NY.
Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy of Casablanca, King Hassan II University, Casablanca, Morocco.
J Exp Med. 2020 May 4;217(5). doi: 10.1084/jem.20192319.
Type I interferonopathies are monogenic disorders characterized by enhanced type I interferon (IFN-I) cytokine activity. Inherited USP18 and ISG15 deficiencies underlie type I interferonopathies by preventing the regulation of late responses to IFN-I. Specifically, USP18, being stabilized by ISG15, sterically hinders JAK1 from binding to the IFNAR2 subunit of the IFN-I receptor. We report an infant who died of autoinflammation due to a homozygous missense mutation (R148Q) in STAT2. The variant is a gain of function (GOF) for induction of the late, but not early, response to IFN-I. Surprisingly, the mutation does not enhance the intrinsic activity of the STAT2-containing transcriptional complex responsible for IFN-I-stimulated gene induction. Rather, the STAT2 R148Q variant is a GOF because it fails to appropriately traffic USP18 to IFNAR2, thereby preventing USP18 from negatively regulating responses to IFN-I. Homozygosity for STAT2 R148Q represents a novel molecular and clinical phenocopy of inherited USP18 deficiency, which, together with inherited ISG15 deficiency, defines a group of type I interferonopathies characterized by an impaired regulation of late cellular responses to IFN-I.
I 型干扰素病是一种单基因疾病,其特征是 I 型干扰素(IFN-I)细胞因子活性增强。USP18 和 ISG15 的遗传性缺陷通过阻止 IFN-I 晚期反应的调节而导致 I 型干扰素病。具体来说,USP18 被 ISG15 稳定,阻碍了 JAK1 与 IFN-I 受体的 IFNAR2 亚基结合。我们报告了一名婴儿因 STAT2 中的纯合错义突变(R148Q)而死于自身炎症。该变体是诱导 IFN-I 晚期反应(而非早期反应)的功能获得性(GOF)。令人惊讶的是,该突变不会增强负责 IFN-I 刺激基因诱导的含 STAT2 的转录复合物的固有活性。相反,STAT2 R148Q 变体是 GOF,因为它不能将 USP18 适当地转运到 IFNAR2,从而阻止 USP18 负调节对 IFN-I 的反应。STAT2 R148Q 纯合性代表了遗传性 USP18 缺陷的一种新型分子和临床表型,与遗传性 ISG15 缺陷一起,定义了一组 I 型干扰素病,其特征是 IFN-I 晚期细胞反应的调节受损。